Reed Smith White Paper on Major Health Care Policy, Funding Provisions in CARES Act

The United States recently passed the “Coronavirus Aid, Relief, and Economic Security Act” (CARES Act), sweeping legislation that could impact pharmaceutical and medical device companies with U.S. operations or significant U.S. sales.

A team of Reed Smith life sciences and health care lawyers, including Scot T. Hasselman, Robert J. Hill, Carol Colborn Loepere, Kevin M. Madagan, Paul W. Pitts, James F. Segroves, Nicole J. Aiken-Shaban, Julia Krebs-Markrich, Debra A. McCurdy, John D. Kendzior, Jamie Knauer, Arielle R. Lusardi, Rahul Narula, Sonia T. Nguyen, Sung W. Park, and Ryan M. Pate has authored a white paper that provides in-depth analysis of major policy and funding provisions in the Act. In addition, Reed Smith has published a CARES Act Overview, which covers all portions of the Act, and is compiling additional thought leadership at our CARES Act Resource Center.